MRI-based assessment of the risk factor for hepatocellular carcinoma of chronic hepatitis type C after anti-viral therapy

MRI-based assessment of the risk factor for hepatocellular carcinoma of chronic hepatitis type C after anti-viral therapy - MRI for stratifying the risk of HCC after SVR by DAA

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000034136

Enrollment

1000

Registered

2018-09-14

Start date

2017-03-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type C hepatitis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who have achieved SVR within 1 year or who is scheduled to receive DAA treatment

Exclusion criteria

Exclusion criteria: Patients who have not achieved SVR by DAA Patients who cannot undergo MRI within 1 year after SVR. Patients of <18 years old

Design outcomes

Primary

Measure	Time frame
HCC development	—

Countries

Japan

Contacts

Public ContactUtaroh Motosugi

University of Yamanashi Radiology

umotosugi@yamanashi.ac.jp055-273-1111

Outcome results